The NanoTherapeutics team aims to exploit the properties of nanoparticles and their interactions with cells and tissues for the development of safe and effective medicines, using clinically-relevant disease models. Our mission is to further the progress of nanomedicine toward clinical translation, particularly in disease areas failed by conventional drugs and therapies.
NanoTherapeutics Research Projects
2D nanomaterials for enhanced cancer immunotherapies
We are investigating the application of graphene and other 2D nanomaterials for more targeted and effective cancer immunotherapies. Current immunotherapy approaches are often limited by their inability to incite effective systemic immune responses and can be associated with dose-limiting off-target immune toxicities. Using 2D nanomaterials as a delivery system we hope to provide more targeted and synchronous induction of innate and adaptive immunity to overcome these limitations.
Developing advanced local drug delivery systems for infiltrating brain tumours
We are exploring nanoparticles and their advantageous distribution in tumour tissue for the development of local drug delivery systems. For this work we focus on using advanced orthotopic cancer models and delivery systems that are the most clinically relevant for each case. The versatility of nanoparticles enables exploration of different therapeutic modalities alone or in combination (chemotherapy, radiotherapy and immunotherapy).
Modulating the fate and behaviour of cells in vivo
We are investigating approaches to directly modulate cell fate and behaviour in vivo for applications in regenerative medicine. In this project we utilise a gene therapy approach to directly modulate cells in situ to support the more effective repair of diseased or injured tissue.
Dr. Thomas Kisby
Senior ResearcherNanoTherapeutics Team Leader
Dr. Lorena Fernandes
Ms. Maria Stylianou
Ms. Mang Xu
Ms. Lydia Thompson
Dr. Yu Siong Ho
Research Lab Manager & Research Assistant
bioRxiv, 2024, doi.org/10.1101/2023.09.18.558196
Engineering the glioblastoma microenvironment using TLR7/8 agonist-complexed graphene oxide nanosheets
bioRxiv, 2023, doi.org/10.1101/2023.08.22.553542
Engineering of a graphene oxide-based two-dimensional platform for immune activation and modulation
Advanced Healthcare Materials, 2022, 2201968
Graphene oxide nanoscale platform enhances the anti-cancer properties of bortezomib in glioblastoma models
Nature Nanotechnology, 2021, 16 (8), 843-850
Reasons for success and lessons learnt from nanoscale vaccines against COVID-19
PLOS ONE, 2021, 16 (5), e0251054
Transient reprogramming of postnatal cardiomyocytes to a dedifferentiated state
Advanced Therapeutics, 2021, 4 (1), 2000109
Deep tissue translocation of graphene oxide sheets in human glioblastoma 3D spheroids and an orthotopic xenograft model
Advanced Therapeutics, 2020, 4 (2), 2000141
Adenoviral mediated delivery of OSKM factors induces partial reprogramming of mouse cardiac cells in vivo
Professor Kostarelos founded in 2006 and is still acting as the Senior Editor the journal Nanomedicine (Future Medicine, London).
Nanomedicine was the first medicine-oriented journal in the field, addressing the important advances and challenges towards the clinical use of nanoscale-structured materials and devices.
Professor Kostarelos also sits on the Editorial Advisory Board of: